HomeCompareSLVRF vs PFE

SLVRF vs PFE: Dividend Comparison 2026

SLVRF yields 512.16% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SLVRF wins by $73978.63M in total portfolio value
10 years
SLVRF
SLVRF
● Live price
512.16%
Share price
$0.39
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73978.68M
Annual income
$53,449,472,856.81
Full SLVRF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — SLVRF vs PFE

📍 SLVRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSLVRFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SLVRF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SLVRF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SLVRF
Annual income on $10K today (after 15% tax)
$43,533.93/yr
After 10yr DRIP, annual income (after tax)
$45,432,051,928.29/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, SLVRF beats the other by $45,432,029,608.38/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SLVRF + PFE for your $10,000?

SLVRF: 50%PFE: 50%
100% PFE50/50100% SLVRF
Portfolio after 10yr
$36989.37M
Annual income
$26,724,749,557.76/yr
Blended yield
72.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

SLVRF
No analyst data
Altman Z
62.7
Piotroski
2/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SLVRF buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSLVRFPFE
Forward yield512.16%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$73978.68M$49.6K
Annual income after 10y$53,449,472,856.81$26,258.71
Total dividends collected$72204.31M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SLVRF vs PFE ($10,000, DRIP)

YearSLVRF PortfolioSLVRF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$61,916$51,216.39$9,153$693.39+$52.8KSLVRF
2$362,618$296,367.65$8,593$849.25+$354.0KSLVRF
3$2,010,151$1,622,149.91$8,336$1,066.78+$2.00MSLVRF
4$10,554,869$8,404,006.67$8,437$1,384.80+$10.55MSLVRF
5$52,534,471$41,240,761.84$9,013$1,875.40+$52.53MSLVRF
6$248,049,794$191,837,910.21$10,306$2,680.72+$248.04MSLVRF
7$1,111,948,756$846,535,475.91$12,820$4,101.38+$1111.94MSLVRF
8$4,736,344,968$3,546,559,799.19$17,673$6,826.70+$4736.33MSLVRF
9$19,186,177,945$14,118,288,828.71$27,543$12,591.86+$19186.15MSLVRF
10$73,978,683,258$53,449,472,856.81$49,560$26,258.71+$73978.63MSLVRF

SLVRF vs PFE: Complete Analysis 2026

SLVRFStock

Silver One Resources Inc., together with its subsidiary, acquires, explores for, and develops silver properties in Canada and the United States. The company holds an option to acquire a 100% interest in the Candelaria silver project located in Nevada. It also holds interest in the Cherokee project covering an area of 5,200 hectares located in Nevada; and an option to acquire a 100% interest in the Phoenix silver property that consists of 86 unpatented lode claims and 2 unpatented placer claims located in Gila County, Arizona. The company was formerly known as BRS Ventures Ltd. and changed its name to Silver One Resources Inc. in September 2016. Silver One Resources Inc. was incorporated in 2007 and is headquartered in Vancouver, Canada.

Full SLVRF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this SLVRF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SLVRF vs SCHDSLVRF vs JEPISLVRF vs OSLVRF vs KOSLVRF vs MAINSLVRF vs JNJSLVRF vs MRKSLVRF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.